Lung Carcinoma (NSCLC) Profile Test in New-panvel

The "Lung Carcinoma (NSCLC) Profile" is a comprehensive test used to evaluate specific markers and genetic alterations in non-small cell lung carcinoma (NSCLC). It involves the analysis of lung tissue obtained through a tru-cut biopsy and includes the following components: Reflex Immunohistochemistry (IHC): Immunohistochemistry is a technique that uses antibodies to detect specific proteins in tumor tissue. In this profile, reflex IHC is used to assess the presence of two critical biomarkers: EGFR & ALK. EGFR (Epidermal Growth Factor Receptor) Mutation Detection: The test specifically detects mutations in two common EGFR exons - Exon 19 deletion and Exon 21 L858R. EGFR mutations are important molecular markers in NSCLC and can guide treatment decisions, as certain targeted therapies are available for patients with EGFR-mutated tumors. ALK (Anaplastic Lymphoma Kinase) IHC: ALK rearrangements are another genetic alteration found in a subset of NSCLC patients. ALK IHC is used as a screening tool to identify tumors with ALK rearrangements, and if positive, further confirmatory tests are conducted. The results of this profile provide valuable information to guide personalized treatment strategies for patients with NSCLC. Based on the detected biomarkers, targeted therapies can be considered to improve treatment outcomes and potentially avoid unnecessary exposure to ineffective treatments. Additionally, the profile aids in disease prognosis and monitoring to assess treatment response over time.